Fount of Information

TriLink BioTechnologies社 Top Nucleic Acid Research Highlights: Advancements You Can't Miss

この製品に関するご意見・ご照会・お問合せはこちら

TriLink_Logo.png

TriLink_Stay1.jpg

Research news

Lipid nanoparticle-mRNA for base editing of congenital brain disease

Genetic central nervous system (CNS) diseases often begin before birth, causing significant morbidity by the time of birth. Prenatal DNA sequencing allows early identification and treatment using mRNA-based gene editing tools like CRISPR-Cas9. In utero, gene editing can maximize therapeutic doses and utilize the tolerant fetal immune system.

In this blog, we explore the development of lipid nanoparticles (LNPs) for delivering mRNA base-editing platforms to fetal mouse and monkey brains, demonstrating brain-cell selectivity and efficient gene modulation.

Read more 

In other research news 

TriLink_TopNucleicAcid1.jpg TriLink_TopNucleicAcid2.jpg

Multi-factor genome editing offers improved outcomes for HIV-1 treament

A cure for HIV could be one step closer with the development of a targeted genome editing strategy for autologous hematopoietic stem and progenitor cell transplantation. Learn how TriLink’s sgRNA facilitated this work in our latest Research Spotlight.

Read more 

A universal STING mimic boosts anti-tumor immunity

The blog discusses a new STING mimic called uniSTING, which activates tumor control pathways independently of endogenous STING expression, showing promising anti-tumor efficacy in vivo when delivered via CleanCap® mRNA encapsulated into lipid nanoparticles.

Read more

 

Our latest advancements

Discover new tools and products

TriLink_TopNucleicAcid3.jpg

TriLink is excited to start offering rNTPs with ≥99% purity in both research-use-only (RUO) and good manufacturing practice (GMP) grades, enabling you to seamlessly transition from research and discovery to clinical development.


Providing confidence in RNA manufacturing, our rNTPs are designed for:


  • Quality — Built phase appropriately with orthogonal analytical methods for therapeutic and diagnostic development, from discovery to commercialization
  • Reliability — Batch-to-batch quality consistency stemming from >25 years of nucleic acid innovation, expertise, and manufacturing
  • Versatility — Catalog sizes, custom aliquots, bulk offerings, and special packaging to suit diverse applications

Discover rNTP offerings ➔ 

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。